List of Excipients in Branded Drug OXYGEN/HELIUM 25/75

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
MATHESON TRI-GAS INC	OXYGEN/HELIUM 25/75	oxygen/helium 25/75	55037-610	HELIUM
MATHESON TRI-GAS INC	OXYGEN/HELIUM 25/75	oxygen/helium 25/75	55037-612	HELIUM

Oxygen/Helium 25/75: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 4, 2026

Oxygen/helium 25/75 is a medical-gas blend containing 25% oxygen and 75% helium. It is commonly categorized as heliox. The product has no conventional excipient strategy because both components are active medical gases, not an active pharmaceutical ingredient combined with inactive formulation materials. Commercial value is concentrated in gas quality, cylinder and delivery systems, manufacturing controls, hospital distribution, and clinical workflow integration.

The strongest opportunity is a regulated, ready-to-use respiratory-gas product for selected airway-obstruction and pulmonary-function applications. The weakest opportunity is composition-based patent protection. A 25/75 oxygen-helium mixture is unlikely to support a durable composition-of-matter monopoly without proprietary delivery hardware, manufacturing controls, or a clinically differentiated use.

What is oxygen/helium 25/75?

Oxygen/helium 25/75 contains:

Component	Concentration	Functional role
Oxygen	25% by volume	Supports oxygenation
Helium	75% by volume	Reduces gas density and airway resistance
Conventional excipients	0%	Not applicable

Helium has substantially lower density than nitrogen-containing air. When oxygen is blended with helium, the resulting gas can reduce turbulent flow through narrowed airways. The clinical rationale is strongest where airway resistance, rather than alveolar oxygen-transfer failure, is the principal problem.

Potential clinical uses include:

• Upper-airway obstruction
• Severe asthma with airflow limitation
• Croup and other obstructive airway conditions
• Difficult airway management
• Pulmonary-function testing
• Specialized respiratory therapy
• Selected emergency-department and intensive-care applications

Heliox does not remove the need to treat the underlying cause of respiratory compromise. Its benefit can diminish when the patient requires high inspired oxygen concentrations because increasing oxygen reduces the helium fraction.

Does oxygen/helium 25/75 contain excipients?

No. Oxygen and helium are the formulation components and the pharmacologically relevant contents of the product.

A conventional pharmaceutical excipient, such as a buffer, preservative, stabilizer, surfactant, or carrier, is generally unsuitable for an inhaled compressed-gas product. Adding a third gas could alter density, oxygen concentration, flammability controls, toxicology, or clinical performance. The commercial formulation objective is therefore not excipient optimization. It is control of:

• Gas identity
• Blend ratio
• Moisture
• Particulate contamination
• Hydrocarbon contamination
• Cylinder compatibility
• Pressure and fill volume
• Valve configuration
• Label accuracy
• Delivery-system performance

The closest equivalent to an excipient strategy is a container-closure and delivery-system strategy.

What formulation attributes are commercially important?

The 25/75 ratio is the principal product specification. Small deviations can affect both oxygen delivery and gas-density reduction. A commercial product should establish validated blend uniformity and release testing for each cylinder or batch.

Gas purity and moisture control

Medical-gas quality depends on control of contaminants that are less relevant in ordinary industrial gas supply. The manufacturing process should address:

• Water vapor
• Carbon monoxide
• Carbon dioxide
• Nitrogen and other residual gases
• Hydrocarbons
• Particles
• Cross-contamination from shared equipment

USP standards and FDA medical-gas requirements provide the principal quality framework for medical gases and their production systems (U.S. Pharmacopeial Convention, 2024; FDA, 2018).

Cylinder and valve design

Commercial differentiation can arise from:

• Lightweight cylinders
• Integrated regulators
• Demand valves
• Low-pressure hospital connectors
• Emergency-department-ready kits
• Portable systems for transport
• Cylinder tracking and refill logistics
• Tamper-evident seals
• Barcoded or RFID-enabled inventory systems

The product should be compatible with the intended ventilator, mask, nebulizer, anesthesia machine, or pulmonary-function instrument. Compatibility failures can eliminate the clinical value of the blend even when gas quality is compliant.

Humidification and delivery accessories

Heliox is commonly delivered through masks, hoods, nasal interfaces, ventilator circuits, or other respiratory equipment. Humidification, flow-meter calibration, and leak management require validation because helium has different physical properties from air and oxygen.

A manufacturer should avoid treating the gas cylinder as the entire product. The higher-value commercial package is a validated gas-plus-delivery platform.

What is the FDA regulatory status of oxygen/helium 25/75?

Medical gases are regulated as drugs in the United States. FDA’s medical-gas framework includes requirements for manufacturing, labeling, current good manufacturing practice, registration and listing, and approval pathways (FDA, 2018).

The applicable pathway depends on the product’s intended use, labeling, manufacturing status, and whether the sponsor markets a new drug product or distributes a gas under an existing regulatory framework. A sponsor cannot assume that a commonly used clinical gas mixture is exempt from drug regulation merely because its ingredients are elemental gases.

Relevant regulatory considerations include:

Regulatory issue	Commercial implication
Drug establishment registration	Required for applicable manufacturers and processors
Drug listing	Product identity and labeling must be reported as required
cGMP compliance	Gas production, testing, filling, and distribution require controls
Labeling	Concentration, warnings, storage, handling, and intended use must be accurate
Container controls	Cylinders, valves, regulators, and closures require qualification
Manufacturing change control	Supplier, equipment, blend, or fill changes may require assessment
Clinical claims	Disease-treatment claims can affect approval and labeling requirements
Device combination	Delivery equipment may create separate device obligations

A product sold solely as an industrial gas has a different regulatory position from a product labeled for treatment or prevention of disease. Medical labeling, hospital purchasing, and clinical promotion should therefore be aligned before commercialization.

What is the Orange Book status of oxygen/helium 25/75?

A simple oxygen/helium 25/75 product should not be expected to have a substantial Orange Book patent estate.

The Orange Book lists FDA-approved drug products and, where applicable, patent and exclusivity information associated with approved products. A product’s inclusion depends on its approved regulatory status and the FDA listing applicable to the product, not merely on the fact that clinicians use the gas mixture.

Potentially relevant Orange Book categories are:

• Composition patents
• Formulation patents
• Method-of-use patents
• Device or delivery claims, where properly linked to an approved drug product
• Regulatory exclusivity associated with an approved application

For a basic 25/75 gas mixture, the commercial protection is more likely to come from operational execution than from Orange Book-listed patents. Patent status must be checked against the specific sponsor, product name, NDA or application number, and jurisdiction. A generic statement that all 25/75 oxygen/helium products share one patent position would be unreliable.

What patents could protect an oxygen/helium 25/75 product?

Composition patents

A patent directed only to oxygen and helium at a 25/75 ratio would face a high patentability risk if the mixture and its respiratory use were already known. Novelty and inventive-step issues would be central.

A stronger composition claim would require a technically meaningful limitation, such as:

• A narrow concentration range with demonstrated clinical benefit
• Defined impurity limits
• A specific humidity range
• A storage-pressure limitation
• A novel premixing process
• A composition optimized for a particular delivery device
• A clinically verified performance advantage over known heliox ratios

Manufacturing patents

Manufacturing protection may be more practical than composition protection. Potential claim areas include:

• Sequential or continuous blending
• Automated ratio control
• In-line analytical release testing
• Cylinder filling methods
• Prevention of component stratification
• Purging and evacuation protocols
• Portable cartridge filling
• Low-temperature or pressure-management techniques

The patent value depends on whether the process reduces cost, improves reproducibility, or satisfies a meaningful regulatory specification.

Delivery-system patents

The strongest proprietary opportunity may involve a delivery system designed specifically for heliox. Claimable features could include:

• Flow compensation
• Helium-specific flow measurement
• Automatic oxygen-concentration monitoring
• Leak compensation
• Integrated humidification
• Ventilator control algorithms
• Portable emergency delivery
• Oxygen rescue or automatic switching
• Patient-triggered demand delivery

These claims would often involve both drug and medical-device considerations. A sponsor should avoid assuming that a device patent alone creates pharmaceutical exclusivity.

Method-of-use patents

Method-of-use claims could target specific patient populations, treatment settings, or delivery parameters. Possible areas include:

• A defined oxygen concentration range for upper-airway obstruction
• Heliox use with a specified ventilatory mode
• Emergency treatment before intubation
• Use with a defined pulmonary-function protocol
• A dosing or flow algorithm based on respiratory mechanics

Method-of-use patents require credible clinical support. Broad claims covering all respiratory obstruction would face prior-art and enablement challenges.

When does oxygen/helium 25/75 lose exclusivity?

There is no universal expiration date for the 25/75 blend itself. A gas mixture does not have a single product-wide exclusivity date unless a particular sponsor has obtained enforceable patent or regulatory rights.

The relevant dates are product-specific:

Protection type	Typical protection question
Composition patent	When does the patent expire, including any term adjustment?
Manufacturing patent	Can competitors use a non-infringing production process?
Delivery patent	Can hospitals use competing regulators or ventilators?
Method-of-use patent	Which labeled or off-label uses remain exposed?
Regulatory exclusivity	Was exclusivity granted for the specific approved application?
Trade secret	Can competitors reproduce the process without access to confidential information?

For a basic oxygen/helium blend, competitors may be able to launch once they satisfy applicable regulatory, quality, labeling, and supply requirements. Patent risk is likely to center on narrowly drafted manufacturing, delivery, or use claims rather than on the gas ratio alone.

Are Paragraph IV challenges likely?

A Paragraph IV challenge is relevant only if an approved reference product has listed patents and a follow-on applicant files an ANDA relying on that reference product.

For oxygen/helium 25/75, a Paragraph IV pathway may be less straightforward than for a conventional small-molecule tablet or injectable because:

1. The product is a gas mixture rather than a conventional dosage form.
2. The reference product may not have a meaningful Orange Book patent listing.
3. Product sameness can involve gas specification, container, valve, delivery system, and labeling.
4. A follow-on sponsor may need a different regulatory route depending on the reference product.

Where listed patents exist, likely challenges would target:

• Non-infringement of concentration-range claims
• Invalidity based on prior heliox disclosures
• Obviousness of the 25/75 ratio
• Lack of written description for broad clinical-use claims
• Inapplicability of device-related claims to the follow-on product

The absence of a composition patent does not eliminate regulatory or commercial barriers. Hospitals may still require validated compatibility, uninterrupted supply, and quality documentation.

What generic entry risks exist?

Generic or competing entry risk is high for an unpatented gas blend but moderate for a fully integrated product platform.

High-risk areas for the incumbent

• Basic 25/75 gas composition
• Standard cylinders
• Commodity helium and oxygen sourcing
• Conventional hospital distribution
• Broad claims based only on heliox use
• Publicly known blending methods

Lower-risk areas

• Proprietary portable delivery systems
• Automated oxygen rescue mechanisms
• Validated ventilator integration
• High-reliability emergency kits
• Proprietary filling and quality-control systems
• Contracted hospital networks
• Specialized clinical protocols
• Supply arrangements with respiratory-equipment manufacturers

The principal competitive threat may come from regional medical-gas suppliers rather than traditional generic-drug companies.

What are the commercial opportunities?

Hospital respiratory care

Hospitals may purchase heliox for emergency departments, intensive-care units, pediatric respiratory care, anesthesia, and pulmonary laboratories. The opportunity is strongest where the product can be delivered immediately without complex setup.

A commercial package could include:

• Preconfigured cylinders
• Regulators calibrated for helium-containing mixtures
• Disposable delivery circuits
• Emergency-department carts
• Clinical-use protocols
• Staff training
• Replenishment agreements

Emergency transport

Portable heliox kits could target ambulance services, air transport, and interfacility transfer. The product must address weight, cylinder duration, temperature exposure, regulator compatibility, and rapid switching to higher oxygen concentrations.

Pulmonary-function testing

Helium-containing gases have applications in pulmonary-function testing and respiratory physiology. A supplier can sell standardized cylinders, calibration gas, accessories, and service contracts. This segment may be less exposed to clinical-claims restrictions than disease-treatment promotion, although labeling must still match the intended use.

Contract manufacturing

Hospitals and smaller medical-gas distributors may outsource blending, filling, labeling, testing, and cylinder management. A manufacturer with validated systems can supply private-label products without relying on patent exclusivity.

Equipment partnerships

The most defensible commercial model may pair the gas with:

• Ventilator manufacturers
• Respiratory-device companies
• Anesthesia-equipment suppliers
• Pulmonary-function-system manufacturers
• Hospital group purchasing organizations
• Emergency medical-service providers

The partnership objective is to make the blend operationally convenient and technically validated.

How does oxygen/helium 25/75 compare with other heliox ratios?

Blend	Oxygen content	Commercial positioning
Oxygen/helium 25/75	25%	Strong helium fraction with modest oxygen support
Oxygen/helium 20/80	20%	Greater density reduction but less oxygen than ambient air
Oxygen/helium 30/70	30%	Higher oxygen support with reduced helium effect
Oxygen/helium 40/60	40%	More oxygen, less density-reduction benefit
Oxygen/helium 50/50	50%	Higher oxygen delivery, weaker heliox characteristics

The commercial choice is a clinical and operational tradeoff. Higher oxygen concentrations may be needed for hypoxemia, but they reduce the relative amount of helium and may reduce the flow benefit. A 25/75 product can be positioned where gas-density reduction is important and the patient does not require a high inspired oxygen concentration.

A sponsor should not assume that one ratio is clinically interchangeable with another. Each blend requires appropriate labeling, clinical support, and delivery validation.

How strong is the patent estate for oxygen/helium 25/75?

The base composition has low expected patent strength unless supported by a genuinely novel technical limitation. The stronger protection strategy is layered:

1. Product specification claims for tightly controlled purity and moisture.
2. Manufacturing claims for reproducible blending and filling.
3. Delivery-system claims for helium-specific flow management.
4. Method-of-use claims supported by defined clinical protocols.
5. Trade secrets covering quality-control methods and supply operations.
6. Contractual protection through hospital and equipment partnerships.

This approach does not create traditional pharmaceutical exclusivity. It creates switching costs and execution advantages. The commercial moat is likely to be strongest where the supplier owns the cylinder fleet, controls delivery equipment, has validated hospital interfaces, and provides dependable replenishment.

What manufacturing and IP barriers affect market entry?

Key barriers include:

• Medical-gas manufacturing compliance
• Access to helium supply
• High-pressure cylinder infrastructure
• Specialized filling equipment
• Gas-analysis instrumentation
• Cylinder testing and maintenance
• Medical-device compatibility
• Distribution density
• Hospital vendor qualification
• Product liability controls
• Emergency supply continuity

Helium sourcing creates a supply-chain risk because helium is a finite and strategically important industrial gas. A commercial plan should use multiple qualified sources where possible and maintain inventory policies that account for supply disruption.

The manufacturing process should segregate medical and industrial gas operations or apply validated controls that prevent contamination. Equipment, cylinders, valves, and regulators must be suitable for oxygen service and handled under oxygen-safety procedures.

What licensing deals are most relevant?

The most valuable licensing opportunities are likely to involve technology and distribution rather than a basic gas composition patent.

Potential deal structures include:

Partner	Licensable asset
Respiratory-device company	Integrated delivery hardware and control software
Ventilator manufacturer	Heliox-compatible operating modes
Medical-gas supplier	Regional manufacturing and distribution rights
Hospital network	Preferred-supplier or exclusive procurement agreement
Pulmonary-equipment company	Testing-gas integration
EMS provider	Portable emergency delivery platform
Contract manufacturer	Private-label production and regulatory support

A licensor should retain control over product specifications, change control, adverse-event reporting, and manufacturing audits. A distributor agreement should define cylinder ownership, refill obligations, geographic territory, inventory service levels, and responsibility for hospital complaints.

What generic launch scenarios should a rights holder expect?

Scenario 1: Commodity-gas competition

A competitor offers the same 25/75 ratio in standard cylinders. Price pressure is high. Differentiation depends on availability, purity documentation, delivery speed, and hospital contracts.

Scenario 2: Device-enabled competition

A competitor launches an integrated regulator or ventilator interface. The incumbent may retain an advantage if its delivery system is patented or contractually embedded in hospital workflows.

Scenario 3: Clinical-use expansion

A sponsor develops evidence for a defined patient population or treatment protocol. This can support method-of-use protection and premium pricing, although clinical adoption remains dependent on guideline acceptance and reimbursement.

Scenario 4: Supply-constrained market

Helium shortages or logistics disruptions increase the value of reliable sourcing and cylinder inventory. Supply continuity becomes a commercial differentiator independent of patent rights.

Key Takeaways

• Oxygen/helium 25/75 is a medical-gas blend, not a conventional excipient-based pharmaceutical formulation.
• The product contains no conventional inactive excipients.
• The core commercial specification is 25% oxygen and 75% helium, supported by purity, moisture, pressure, and container controls.
• Composition-based patent protection is likely weak unless a novel technical limitation exists.
• Manufacturing, delivery-system, and method-of-use patents offer more practical protection.
• FDA medical-gas compliance, labeling, cGMP controls, cylinder management, and device compatibility are central entry requirements.
• Orange Book and Paragraph IV risk depends on the specific reference product and listed patents.
• The strongest business model combines validated gas supply with regulators, ventilator integration, emergency kits, and hospital distribution.
• Generic entry risk is high for the base gas blend and lower for a proprietary gas-plus-device platform.
• Licensing opportunities are more likely to involve delivery technology, manufacturing, and distribution than the 25/75 composition itself.

FAQs

Is oxygen/helium 25/75 the same as heliox?

Yes. Oxygen/helium 25/75 is a heliox blend containing 25% oxygen and 75% helium. The term heliox also covers other oxygen-helium ratios.

Can nitrogen be considered an excipient in an oxygen/helium blend?

No. Nitrogen would be a formulation component or contaminant, depending on the intended specification. It is not a conventional excipient.

Does heliox require a special flow meter?

Often yes. Helium changes gas density and can affect the accuracy of flow meters calibrated for air or oxygen. The delivery system should be validated for the specific blend.

Can an oxygen/helium mixture receive new-drug exclusivity?

Potentially, if a sponsor obtains an applicable FDA approval and satisfies the requirements for regulatory exclusivity. The availability and duration depend on the specific application and product.

Is helium supply a patent issue?

No. Helium supply is primarily a sourcing, logistics, and supply-continuity issue. It can become a commercial barrier even when the product has little composition-based patent protection.

References

1. U.S. Food and Drug Administration. (2018). Medical gas regulation. https://www.fda.gov
2. U.S. Food and Drug Administration. (2018). Medical gas final rule. Federal Register, 83 Fed. Reg. 38696.
3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. General chapters concerning medical gases and pharmaceutical compounding.
5. U.S. Food and Drug Administration. (n.d.). Current good manufacturing practice for drugs. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations-part-210-and-part-211